LONDON – Evotec AG has out-licensed its lead monoamine oxidase type B (MAO-B) product for Alzheimer's disease in a $830 million deal with Roche AG, taking $10 million up front, followed by short-term clinical milestones of $170 million and the balance to come in commercial milestones.